These authors contributed equally to this work.
Dengue virus inactivation by minipool TnBP/Triton X-45 treatment of plasma and cryoprecipitate
Article first published online: 4 JUL 2012
© 2012 The Author(s). Vox Sanguinis © 2012 International Society of Blood Transfusion
Volume 104, Issue 1, pages 1–6, January 2013
How to Cite
Burnouf, T., Chou, M.-L., Cheng, L.-H., Li, Z.-R., Wu, Y.-W., El-Ekiaby, M. and Tsai, K.-H. (2013), Dengue virus inactivation by minipool TnBP/Triton X-45 treatment of plasma and cryoprecipitate. Vox Sanguinis, 104: 1–6. doi: 10.1111/j.1423-0410.2012.01621.x
- Issue published online: 17 DEC 2012
- Article first published online: 4 JUL 2012
- Received: 31 March 2012; revised 7 May 2012; accepted 7 May 2012
Background and Objectives A minipool solvent/detergent (S/D; 1% TnBP/1% Triton X-45; 31°C) process was developed for viral inactivation of plasma and cryoprecipitate used for transfusion. The goal of this study was to determine the rate and extent of inactivation of dengue virus (DENV) during this process.
Materials and Methods DENV-1 was propagated using C6/36 mosquito cells to an infectivity titre close to 9 log and spiked (10% v/v) into individual plasma and cryoprecipitate samples from two distinct donors. Samples were taken right after spiking and during viral inactivation treatment by 1% TnBP-1% Triton X-45 at 31°C. DENV-1 infectivity was assessed on Vero E6 cells by a focus-forming assay (FFA). Culture medium and complement-inactivated plasma were used as experimental controls. Experiments were done in duplicate.
Results DENV-1 infectivity was 7·5 log in spiked plasma and 7·1 and 7·3 log in spiked cryoprecipitate. There was no loss of DENV-1 infectivity in the spiked materials, nor in the controls not subjected to S/D treatment. No infectivity was found in plasma and cryoprecipitate subjected to S/D treatment at the first time-point evaluated (10 min).
Conclusion DENV-1 was strongly inactivated in plasma and cryoprecipitate, respectively, within 10 min of 1% TnBP/1% Triton X-45 treatment at 31°C. These data provide a reassurance of the safety of such S/D-treated plasma and cryoprecipitate with regard to the risk of transmission of all DENV serotypes and other flaviviruses.